The Experts below are selected from a list of 1200 Experts worldwide ranked by ideXlab platform
Kitti Jirarattanaphochai - One of the best experts on this subject based on the ideXlab platform.
-
prevention of peridural fibrosis using a cyclooxygenase 2 inhibitor nonsteroidal anti inflammatory drug soaked in absorbable gelatin sponge an experimental comparative animal model
Spine, 2013Co-Authors: Surachai Saejung, Kitti JirarattanaphochaiAbstract:Abstract Experimental study. To evaluate the efficacy and safety of peridural Parecoxib-soaked absorbable gelatin sponge, and cellulose membrane on peridural fibrosis prevention in an animal model. Postoperative peridural fibrosis is one of the causes of failed back surgery syndrome. Nonsteroidal anti-inflammatory drugs inhibit the inflammatory response, while an absorbable gelatin sponge or cellulose membrane interposes between the dura and the paraspinal muscle to staunch the surgical bleeding. These mechanisms may prevent peridural fibrosis. Forty L5-L6 laminectomized adult Sprague-Dawley rats were randomly allocated into 4 groups. The high Parecoxib group received 6 mg of Parecoxib soaked into an absorbable gelatin sponge placed over the dura. The low Parecoxib group was given 2 mg of Parecoxib soaked into an absorbable gelatin sponge. The dura in the cellulose group was covered with a cellulose membrane, while the control group received normal saline drip before surgical wound closure. All rats were killed at 6 weeks for histopathological assessment. The fibroblast density, inflammatory cell density, fibrous adherence, and adverse events were quantified. The obtained results were analyzed statistically. The respective mean fibroblast density in the high Parecoxib, low Parecoxib, cellulose, and control groups was 217.77 ± 51.76, 317.51 ± 126.92, 321.80 ± 90.94, and 328.48 ± 73.41 cells/mm², while the respective mean inflammatory cell density was 539.65 ± 236.52, 910.17 ± 242.59, 1011.84 ± 239.30, and 1261.78 ± 319.68 cells/mm². The mean fibroblast and inflammatory cell densities of the high Parecoxib group were significantly lower than the control. The high Parecoxib group also showed statistically less fibrous adherence than low Parecoxib, cellulose, and control groups. The high-dose Parecoxib-soaked absorbable gelatin sponge can prevent peridural fibrosis without complications. The low-dose Parecoxib and cellulose membrane provided no significant benefit vis-a-vis prevention of peridural fibrosis, as adduced from the lack of any statistically significant difference between the test and control rats.
-
prevention of peridural fibrosis using a cyclooxygenase 2 inhibitor nonsteroidal anti inflammatory drug soaked in absorbable gelatin sponge an experimental comparative animal model
Spine, 2013Co-Authors: Surachai Saejung, Kitti JirarattanaphochaiAbstract:Study design Experimental study. Objective To evaluate the efficacy and safety of peridural Parecoxib-soaked absorbable gelatin sponge, and cellulose membrane on peridural fibrosis prevention in an animal model. Summary of background data Postoperative peridural fibrosis is one of the causes of failed back surgery syndrome. Nonsteroidal anti-inflammatory drugs inhibit the inflammatory response, while an absorbable gelatin sponge or cellulose membrane interposes between the dura and the paraspinal muscle to staunch the surgical bleeding. These mechanisms may prevent peridural fibrosis. Methods Forty L5-L6 laminectomized adult Sprague-Dawley rats were randomly allocated into 4 groups. The high Parecoxib group received 6 mg of Parecoxib soaked into an absorbable gelatin sponge placed over the dura. The low Parecoxib group was given 2 mg of Parecoxib soaked into an absorbable gelatin sponge. The dura in the cellulose group was covered with a cellulose membrane, while the control group received normal saline drip before surgical wound closure. All rats were killed at 6 weeks for histopathological assessment. The fibroblast density, inflammatory cell density, fibrous adherence, and adverse events were quantified. The obtained results were analyzed statistically. Results The respective mean fibroblast density in the high Parecoxib, low Parecoxib, cellulose, and control groups was 217.77 ± 51.76, 317.51 ± 126.92, 321.80 ± 90.94, and 328.48 ± 73.41 cells/mm², while the respective mean inflammatory cell density was 539.65 ± 236.52, 910.17 ± 242.59, 1011.84 ± 239.30, and 1261.78 ± 319.68 cells/mm². The mean fibroblast and inflammatory cell densities of the high Parecoxib group were significantly lower than the control. The high Parecoxib group also showed statistically less fibrous adherence than low Parecoxib, cellulose, and control groups. Conclusion The high-dose Parecoxib-soaked absorbable gelatin sponge can prevent peridural fibrosis without complications. The low-dose Parecoxib and cellulose membrane provided no significant benefit vis-a-vis prevention of peridural fibrosis, as adduced from the lack of any statistically significant difference between the test and control rats.
-
effect of Parecoxib on postoperative pain after lumbar spine surgery a bicenter randomized double blinded placebo controlled trial
Spine, 2008Co-Authors: Kitti Jirarattanaphochai, Somboon Thienthong, Wimonrat Sriraj, Surachai Jung, Aksorn Pulnitiporn, Somkid Lertsinudom, Thanit FoocharoenAbstract:Study design A bicenter randomized, patients, healthcare providers, and data collectors blind placebo-controlled trial in multimodal analgesia for postoperative lumbar spine surgery was conducted. Objective To assess the efficacy and safety of Parecoxib on postoperative pain management after posterior lumbar spine surgery. Summary of background data Systematic reviews suggest that cyclo-oxygenase-2 inhibitors are an effective treatment for acute postoperative pain. However, previous trials on lumbar spine surgery showed equivocal efficacy of cyclo-oxygenase-2 inhibitors for postoperative pain relief. Methods In this study, 120 patients undergoing posterior lumbar discectomy, spinal decompression, or spinal fusion were stratified based on the surgical procedure to 3 groups (n = 40) and randomly allocated to receive multidoses of Parecoxib 40 mg/dose or placebo. Efficacy was assessed by total morphine used from patient-controlled analgesic pump, pain intensity, pain relief, and the patient's subjective rating of the medication. Results Parecoxib 40 mg reduced the total amount of morphine required over 48 hours by 39% relative morphine reduction compared with placebo (P = 0.0001). Pain at rest was reduced by 30% (P = 0.0001). Ninety percent of patients given Parecoxib experienced at least 50% maximum total pain relief compared with 58% treated with placebo. The number-needed-to-treat for 1 patient to have at least half pain relief was 3.1 (2.0-4.6). Patients' subjective rating of the medication was described as "excellent, good, and fair" by 48%, 43%, and 8% in the Parecoxib group, respectively, compared with 21%, 50%, and 28% of placebo patients (P = 0.004). Overall adverse effects of patients receiving Parecoxib and morphine were comparable to those receiving morphine alone. Conclusion The present study demonstrates that the perioperative administration of Parecoxib with patient-controlled analgesic morphine after lumber spine surgery resulted in significantly improved postoperative analgesic management as defined by reduction in opioid requirement, lower pain scores, and higher patients' subjective rating of the medication.
Richard C Hubbard - One of the best experts on this subject based on the ideXlab platform.
-
a clinical trial demonstrates the analgesic activity of intravenous Parecoxib sodium compared with ketorolac or morphine after gynecologic surgery with laparotomy
American Journal of Obstetrics and Gynecology, 2004Co-Authors: George B Bikhazi, Michael C Snabes, Zahid H Bajwa, Derek J Davis, Diane Lecomte, Louise Traylor, Richard C HubbardAbstract:Objective The purpose of this study was to compare the analgesic activity of 2 doses of Parecoxib sodium, ketorolac, and morphine with placebo after gynecologic surgery that requires laparotomy. Study design In a randomized, controlled, double-blind, parallel-group study, 208 patients, after surgical hysterectomy, received single-dose intravenous placebo, Parecoxib sodium 20 mg or 40 mg, ketorolac 30 mg, or morphine 4 mg followed by multiple-dose Parecoxib sodium or ketorolac as needed. Primary efficacy variables were time to onset of analgesia, pain intensity differences, pain relief, time to first rescue/remedication, and global evaluation of study medication. Results Single-dose Parecoxib sodium 40 mg provided significantly better pain responses to placebo or morphine 4 mg and was comparable to ketorolac 30 mg. Multiple-dose Parecoxib sodium 20 mg, 4 times daily, or 40 mg, twice daily, was comparable to ketorolac 30 mg, 4 times daily. Parecoxib sodium was well tolerated. Conclusion Parecoxib sodium is an effective analgesic in the management of acute postoperative pain after laparotomy surgery.
-
analgesic efficacy of preoperative Parecoxib sodium in an orthopedic pain model
Journal of the American Podiatric Medical Association, 2004Co-Authors: Paul J. Desjardins, Louise Traylor, Richard C HubbardAbstract:The efficacy and safety of preoperative intravenous administration of Parecoxib sodium, a novel parenteral prodrug of a cyclooxygenase-2 selective inhibitor, in treating postoperative pain resulting from bunionectomy were evaluated in 50 patients who were part of a larger cohort of orthopedic and podiatric patients. Following bunionectomy, the median time to rescue medication (survival analysis) was 4 hours 18 min (95% confidence interval, 3 hours 4 min to 4 hours 37 min) in the placebo group, 7 hours 5 min (95% confidence interval, 3 hours 20 min to >24 hours) in the 20-mg Parecoxib sodium group, and 10 hours 43 min (95% confidence interval, 4 hours 42 min to 14 hours 7 min) in the 40-mg Parecoxib sodium group (significant for 40-mg Parecoxib sodium versus placebo). Four or more hours after surgery, the mean pain-intensity (categorical) score was significantly lower in both Parecoxib sodium groups than in the placebo group. Preoperative administration of Parecoxib sodium was well tolerated and significan...
-
efficacy and safety of intravenous Parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery
Anesthesiology, 2002Co-Authors: Scott F Barton, Michael C Snabes, Diane Lecomte, Michael Kuss, Shobha Dhadda, Fred F Langeland, Richard C HubbardAbstract:Background: This study tested the hypothesis that an injectable cyclooxygenase (COX)-2-specific inhibitor will be at least as effective and well tolerated as a COX-nonspecific conventional nonsteroidal antiinflammatory drug (NSAID) by comparing the analgesic efficacy and tolerability of one intravenous dose of Parecoxib sodium, an injectable prodrug of the novel COX-2-specific inhibitor, valdecoxib, with ketorolac and placebo in postoperative laparotomy surgery patients. Intravenous morphine, 4 mg, was studied as a positive analgesic control. Methods: In this multicenter, double-blinded, placebo-controlled study, women experiencing moderate-to-severe pain on the first day after abdominal hysterectomy or myomectomy received one intravenous dose of Parecoxib sodium, 20 or 40 mg, ketorolac, 30 mg, morphine, 4 mg, or placebo. Analgesic efficacy and tolerability were evaluated for 24 h postdose or until patients, whose pain was not adequately controlled, opted to receive rescue analgesia. Results: Two hundred two patients were enrolled. All treatment groups had comparable demographics and baseline pain status. All active treatments had an equally rapid time to onset of analgesia (10-23 min). Overall, each Parecoxib sodium dose and ketorolac were significantly superior to morphine and placebo for most measures of analgesic efficacy at most time points, including a significantly longer (two- to threefold) time to rescue analgesia (P ≤ 0.05). All treatments were well tolerated. Conclusions: Single intravenous doses of Parecoxib sodium, 20 mg and 40 mg, have comparable analgesic effects and are well tolerated after laparotomy surgery. Parecoxib sodium appears to be as effective as intravenous ketorolac, 30 mg, and superior to intravenous morphine, 4 mg.
-
intravenous Parecoxib sodium foracute pain after orthopedic knee surgery
American journal of orthopedics, 2002Co-Authors: Lynn G Rasmussen, Karen Steckner, Charles W Hogue, Sarah Torri, Richard C HubbardAbstract:Our objective in a randomized, multicenter, double-blind, parallel-group, placebo- and active-controlled study was to evaluate and compare the analgesic effectiveness of single intravenous (IV) doses of Parecoxib sodium 20 and 40 mg, morphine 4 mg, and ketorolac 30 mg in the postsurgical orthopedic pain model. After undergoing unilateral total knee replacement surgery, 208 healthy adult patients were randomized to receive placebo or a study drug within 6 hours of discontinuation of patient-controlled analgesia on postoperative day 1. Onset of analgesia was similarly rapid with IV Parecoxib sodium 40 mg, morphine, and ketorolac. Level and duration of analgesia were significantly superior with Parecoxib sodium than with morphine and were similar for Parecoxib sodium and ketorolac. Parecoxib sodium was safe and well tolerated. In conclusion, IV Parecoxib sodium 40 mg is as effective as ketorolac 30 mg and is more effective than morphine 4 mg and therefore has potential widespread utility in acute postoperative pain management.
-
upper gi mucosal effects of Parecoxib sodium in healthy elderly subjects
The American Journal of Gastroenterology, 2002Co-Authors: Randall R Stoltz, Diane Lecomte, Michael E Kuss, Sheela Talwalker, Shobha Dhadda, Stuart I Harris, Richard C HubbardAbstract:Abstract OBJECTIVE: The aim of this study was to compare the upper GI mucosal effects of i.v. Parecoxib sodium with i.v. ketorolac tromethamine and placebo in healthy elderly subjects. METHODS: This was a two-center, double-blind, randomized, placebo-controlled study. Healthy subjects aged 65–75 yr who were shown at baseline endoscopy to have no gastric or duodenal lesions received either Parecoxib sodium 40 mg b.i.d. for 7 days, ketorolac 15 mg q.i.d. for 5 days, or placebo for 7 days. Endoscopy was repeated at the end of dosing. Measures of upper GI effects were: 1) ulceration, 2) incidence of an ulcer and/or any erosions, and 3) incidence of an ulcer and/or ≥11 erosions in the stomach, duodenum, or both. RESULTS: No gastric or duodenal ulcers occurred in any subjects receiving Parecoxib sodium (n = 29) or placebo (n = 32). In contrast, seven (23%) of the 31 ketorolac subjects had at least one ulcer; five (16%) had gastric ulcers, and two (6%) had duodenal ulcers (p CONCLUSIONS: These results indicate that multiple dose administration of Parecoxib sodium is safe and well tolerated in healthy elderly subjects, with a decreased risk of gastroduodenal mucosal injury compared with ketorolac.
Surachai Saejung - One of the best experts on this subject based on the ideXlab platform.
-
prevention of peridural fibrosis using a cyclooxygenase 2 inhibitor nonsteroidal anti inflammatory drug soaked in absorbable gelatin sponge an experimental comparative animal model
Spine, 2013Co-Authors: Surachai Saejung, Kitti JirarattanaphochaiAbstract:Abstract Experimental study. To evaluate the efficacy and safety of peridural Parecoxib-soaked absorbable gelatin sponge, and cellulose membrane on peridural fibrosis prevention in an animal model. Postoperative peridural fibrosis is one of the causes of failed back surgery syndrome. Nonsteroidal anti-inflammatory drugs inhibit the inflammatory response, while an absorbable gelatin sponge or cellulose membrane interposes between the dura and the paraspinal muscle to staunch the surgical bleeding. These mechanisms may prevent peridural fibrosis. Forty L5-L6 laminectomized adult Sprague-Dawley rats were randomly allocated into 4 groups. The high Parecoxib group received 6 mg of Parecoxib soaked into an absorbable gelatin sponge placed over the dura. The low Parecoxib group was given 2 mg of Parecoxib soaked into an absorbable gelatin sponge. The dura in the cellulose group was covered with a cellulose membrane, while the control group received normal saline drip before surgical wound closure. All rats were killed at 6 weeks for histopathological assessment. The fibroblast density, inflammatory cell density, fibrous adherence, and adverse events were quantified. The obtained results were analyzed statistically. The respective mean fibroblast density in the high Parecoxib, low Parecoxib, cellulose, and control groups was 217.77 ± 51.76, 317.51 ± 126.92, 321.80 ± 90.94, and 328.48 ± 73.41 cells/mm², while the respective mean inflammatory cell density was 539.65 ± 236.52, 910.17 ± 242.59, 1011.84 ± 239.30, and 1261.78 ± 319.68 cells/mm². The mean fibroblast and inflammatory cell densities of the high Parecoxib group were significantly lower than the control. The high Parecoxib group also showed statistically less fibrous adherence than low Parecoxib, cellulose, and control groups. The high-dose Parecoxib-soaked absorbable gelatin sponge can prevent peridural fibrosis without complications. The low-dose Parecoxib and cellulose membrane provided no significant benefit vis-a-vis prevention of peridural fibrosis, as adduced from the lack of any statistically significant difference between the test and control rats.
-
prevention of peridural fibrosis using a cyclooxygenase 2 inhibitor nonsteroidal anti inflammatory drug soaked in absorbable gelatin sponge an experimental comparative animal model
Spine, 2013Co-Authors: Surachai Saejung, Kitti JirarattanaphochaiAbstract:Study design Experimental study. Objective To evaluate the efficacy and safety of peridural Parecoxib-soaked absorbable gelatin sponge, and cellulose membrane on peridural fibrosis prevention in an animal model. Summary of background data Postoperative peridural fibrosis is one of the causes of failed back surgery syndrome. Nonsteroidal anti-inflammatory drugs inhibit the inflammatory response, while an absorbable gelatin sponge or cellulose membrane interposes between the dura and the paraspinal muscle to staunch the surgical bleeding. These mechanisms may prevent peridural fibrosis. Methods Forty L5-L6 laminectomized adult Sprague-Dawley rats were randomly allocated into 4 groups. The high Parecoxib group received 6 mg of Parecoxib soaked into an absorbable gelatin sponge placed over the dura. The low Parecoxib group was given 2 mg of Parecoxib soaked into an absorbable gelatin sponge. The dura in the cellulose group was covered with a cellulose membrane, while the control group received normal saline drip before surgical wound closure. All rats were killed at 6 weeks for histopathological assessment. The fibroblast density, inflammatory cell density, fibrous adherence, and adverse events were quantified. The obtained results were analyzed statistically. Results The respective mean fibroblast density in the high Parecoxib, low Parecoxib, cellulose, and control groups was 217.77 ± 51.76, 317.51 ± 126.92, 321.80 ± 90.94, and 328.48 ± 73.41 cells/mm², while the respective mean inflammatory cell density was 539.65 ± 236.52, 910.17 ± 242.59, 1011.84 ± 239.30, and 1261.78 ± 319.68 cells/mm². The mean fibroblast and inflammatory cell densities of the high Parecoxib group were significantly lower than the control. The high Parecoxib group also showed statistically less fibrous adherence than low Parecoxib, cellulose, and control groups. Conclusion The high-dose Parecoxib-soaked absorbable gelatin sponge can prevent peridural fibrosis without complications. The low-dose Parecoxib and cellulose membrane provided no significant benefit vis-a-vis prevention of peridural fibrosis, as adduced from the lack of any statistically significant difference between the test and control rats.
Evan D. Kharasch - One of the best experts on this subject based on the ideXlab platform.
-
simultaneous assessment of drug interactions with low and high extraction opioids application to Parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil
Anesthesiology, 2003Co-Authors: Andra E Ibrahim, Jennifer Feldman, Aziz Karim, Evan D. KharaschAbstract:BACKGROUND Parecoxib is a parenteral cyclooxygenase-2 (COX-2) inhibitor intended for perioperative analgesia. It is an inactive prodrug hydrolyzed in vivo to the active inhibitor valdecoxib, a substrate for hepatic cytochrome P450 3A4 (CYP3A4); hence, a potential exists for metabolic interactions with other CYP3A substrates. This study determined the effects of Parecoxib on the pharmacokinetics and pharmacodynamics of the CYP3A substrates fentanyl and alfentanil compared with the CYP3A inhibitor troleandomycin. Alfentanil is a low-extraction drug with a clearance that is highly susceptible to drug interactions; fentanyl is a high-extraction drug and, thus, is theoretically less vulnerable. We therefore also tested the hypothesis that the extraction ratio influences the consequence of altered hepatic metabolism of these opioids. METHODS After Institutional Review Board-approved, written, informed consent was obtained, 12 22- to 40-yr-old healthy volunteers were enrolled in the study. The protocol was a randomized, double-blinded, balanced, placebo-controlled, three-session (placebo, Parecoxib, or troleandomycin pretreatment) crossover. Subjects received both alfentanil (15 microg/kg) and fentanyl (5 microg/kg; 15-min intravenous infusion) 1 h after placebo, Parecoxib (40 mg intravenously every 12 h), or troleandomycin (every 6 h). Study sessions were separated by 7 or more days. Opioid concentrations in venous blood were determined by liquid chromatography-mass spectrometry. Pharmacokinetic parameters were determined by noncompartmental analysis. Opioid effects were determined by pupillometry, respiratory rate, and Visual Analog Scale scores. RESULTS There were no significant differences between the placebo and Parecoxib treatments in alfentanil or fentanyl plasma concentration, maximum observed plasma concentration, area under the plasma time-concentration time curve, clearance, elimination half-life, or volume of distribution. However, disposition of alfentanil, and to a lesser extent fentanyl, was significantly altered by troleandomycin. Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001). Pupil diameter versus time curves were similar between placebo and Parecoxib treatments but were significantly different after troleandomycin. CONCLUSIONS Single-dose Parecoxib does not alter fentanyl or alfentanil disposition or clinical effects and does not appear to cause significant CYP3A drug interactions. CYP3A inhibition decreases alfentanil clearance more than fentanyl clearance, confirming that the extraction ratio influences the consequence of altered hepatic drug metabolism. Modified cassette, or "cocktail," dosing is useful for assessing drug interactions in humans.
-
the influence of Parecoxib a parenteral cyclooxygenase 2 specific inhibitor on the pharmacokinetics and clinical effects of midazolam
Anesthesia & Analgesia, 2002Co-Authors: Andra E Ibrahim, Jennifer Feldman, Aziz Karim, Evan D. KharaschAbstract:Parecoxib, a parenteral cyclooxygenase-2 inhibitor, is undergoing clinical development as an analgesic/antiinflammatory drug for perioperative use. Parecoxib, an inactive prodrug, is hydrolyzed in vivo to valdecoxib, a substrate for hepatic cytochrome P450 (CYP) 3A4. Thus, potential exists for inter
-
effects of Parecoxib a parenteral cox 2 specific inhibitor on the pharmacokinetics and pharmacodynamics of propofol
Anesthesiology, 2002Co-Authors: Andra E Ibrahim, Jennifer Feldman, Aziz Karim, Sang Park, Evan D. KharaschAbstract:Background Parecoxib, a cyclooxygenase-2-specific inhibitor with intended perioperative analgesic and antiinflammatory use, is a parenterally administered inactive prodrug undergoing rapid hydrolysis in vivo to the active cyclooxygenase-2 inhibitor valdecoxib. Both Parecoxib and valdecoxib inhibit human cytochrome P450 2C9 (CYP2C9) activity in vitro. Thus, a potential exists for in vivo interactions with other CYP2C9 substrates, including propofol. This investigation determined the influence of Parecoxib on the pharmacokinetics and pharmacodynamics of bolus dose propofol in human volunteers. Methods This was a randomized, balanced crossover, placebo-controlled, double-blind, clinical investigation. Twelve healthy 21- to 37-yr-old subjects were studied after providing institutional review board-approved written informed consent. Each subject received a 2-mg/kg intravenous propofol bolus 1 h after placebo (control) or 40 mg intravenous Parecoxib on two occasions. Venous concentrations of propofol, Parecoxib, and Parecoxib metabolites were determined by mass spectrometry. Pharmacokinetic parameters were determined by noncompartmental analysis. Pharmacodynamic measurements included clinical endpoints, cognitive function (memory, Digit-Symbol Substitution Tests), subjective self-assessment of recovery (Visual Analog Scale) performed at baseline, 15, 30, 60 min after propofol, and sedation depth measured by Bispectral Index. Results Propofol plasma concentrations were similar between placebo- and Parecoxib-treated subjects. No significant differences were found in pharmacokinetic parameters (Cmax, clearance, elimination half-life, volume of distribution) or pharmacodynamic parameters (clinical endpoints [times to: loss of consciousness, apnea, return of response to voice], Bispectral Index scores, Digit-Symbol Substitution Test scores, memory, Visual Analog Scale scores, propofol EC(50)). Conclusions Single-bolus Parecoxib, in doses to be used perioperatively, does not alter the disposition or the magnitude or time course of clinical effects of bolus propofol. Effects on a propofol infusion were not evaluated.
Odimba Etienne - One of the best experts on this subject based on the ideXlab platform.
-
Effets du Parecoxib dans la Prévention des Adhérences abdominales postopératoires : étude expérimentale randomisée chez les rats
'African Journals Online (AJOL)', 2016Co-Authors: Arung Willy, Tshilombo François, Odimba EtienneAbstract:Introduction: Bien d'études ont été menées sur les adhérences intrapéritonéales, mais aucune unanimité n'est encore acquise sur leur prévention. Le but de notre étude a été d'évaluer le potentiel effet d'un antiinflammatoire, Parecoxib dans la prévention des adhérences ainsi que sur la cicatrisation chez des rats. Méthodes: Dans un modèle expérimental d'adhérences postopératoires secondaires à des lésions péritonéales par brûlure, 30 rats furent randomisés en trois groupes suivant le mode d'administration de Parecoxib (groupe contrôle; intrapéritonéal; intramusculaire. Résultats: Le Parecoxib a significativement diminué la quantité (p < .05) et la sévérité (p < .01) des adhérences postopératoires dans les deux modèles expérimentaux. Au total, 21 rats ont développé des adhérences, respectivement 9 (100%) dans le groupe A, 5 (50%) dans le groupe B et 7 (70%) dans le groupe C (p=0.05). Du point de vue de la formation des adhérences au site du traumatisme, dix-neuf rats en ont développé : 9 (100%) dans le groupe A et 5 (50%) pour chacun de deux autres groupes B et C. Une différence significative a été constatée en comparant ces groupes deux à deux : A vs B (p<0.05) ; A vs C (p<0,05). Parecoxib n'a pas compromis la cicatrisation intestinale, ni cutanée. Conclusion: Cette étude a montré que le Parecoxib pouvait réduire la formation des adhérences postopératoires. La confirmation de la sécurité du Parecoxib sur les anastomoses intestinales doit être investiguée au cours d'autres expérimentations.Pan African Medical Journal 2015; 2
-
Effets du Parecoxib dans la Prévention des Adhérences abdominales postopératoires : étude expérimentale randomisée chez les rats
'African Journals Online (AJOL)', 2016Co-Authors: Arung Willy, Tshilombo François, Odimba EtienneAbstract:Introduction: Bien d'études ont été menées sur les adhérences intrapéritonéales, mais aucune unanimité n'est encore acquise sur leur prévention. Le but de notre étude a été d'évaluer le potentiel effet d'un antiinflammatoire, Parecoxib dans la prévention des adhérences ainsi que sur la cicatrisation chez des rats. Méthodes: Dans un modèle expérimental d'adhérences postopératoires secondaires à des lésions péritonéales par brûlure, 30 rats furent randomisés en trois groupes suivant le mode d'administration de Parecoxib (groupe contrôle; intrapéritonéal; intramusculaire.Résultats: Le Parecoxib a significativement diminué la quantité (p < .05) et la sévérité (p < .01) des adhérences postopératoires dans les deux modèles expérimentaux. Au total, 21 rats ont développé des adhérences, respectivement 9 (100%) dans le groupe A, 5 (50%) dans le groupe B et 7 (70%) dans le groupe C (p=0.05). Du point de vue de la formation des adhérences au site du traumatisme, dix-neuf rats en ont développé : 9 (100%) dans le groupe A et 5 (50%) pour chacun de deux autres groupes B et C. Une différence significative a été constatée en comparant ces groupes deux à deux : A vs B (p<0.05) ; A vs C (p<0,05). Parecoxib n'a pas compromis la cicatrisation intestinale, ni cutanée. Conclusion: Cette étude a montré que le Parecoxib pouvait réduire la formation des adhérences postopératoires. La confirmation de la sécurité du Parecoxib sur les anastomoses intestinales doit être investiguée au cours d'autres expérimentations. Key words: Adhérence, postopératoire, complications, prévention, expérimentation chirurgicale, modèle animal, cyclooxygenase-2, antiinflammatoire non stéroïdie
